

Message from the Founders and Executive Director

In 1999, the doors of Huntsman Cancer Institute (HCI) opened as the first step toward realizing our common dream: to eradicate cancer. In 2009, we celebrated 10 years of progress toward this goal.

The past decade witnessed the launch of research in our state-of-the-art laboratories and saw HCI develop into a comprehensive cancer campus—a place where individuals faced with cancer receive the most advanced treatment using cutting-edge technology applied by expert oncology care providers.

At the heart of our cancer campus is the world-class research facility. Thanks to unique access to extensive resources in family genetics, HCI investigators have made pivotal discoveries concerning cancer predisposition genes. Our strength in this science provides insights to cancer's very beginnings. The resulting advancements provide a strong foundation from which our scientists investigate cancer pathways, define the characteristics of predictable cancer, and develop all-important screening guidelines to help prevent cancer. Our researchers have discovered mechanisms that initiate tumor formation; they have shed new light on how cancers spread; and they are leading the way to develop individualized oncology treatments uniquely tailored to each patient.

Huntsman Cancer Hospital, a crown jewel of our cancer campus, provides a vital link between laboratory science and patient care. The world-class clinical care offered is enhanced by extensive collaboration among our outstanding translational scientists and clinical researchers to fully personalize cancer treatment.

Scientific discoveries in the laboratory, innovative clinical research in our hospital, and outreach and education throughout Utah communities combine to make HCI a leader in the field. Over the past decade, our cancer campus has extended throughout Utah. Our strategic alliance with Intermountain Healthcare ensures the outstanding resources of HCI are widely accessible via clinical care, clinical trials, and cancer education centers located in Ogden, Murray, American Fork, Cedar City, and St. George.

During the first 10 years of HCI's operation, increasing numbers of Americans have made the leap from being cancer patients to cancer survivors. A decade of discovery has brought us ever closer to realizing our dream, and we remain steadfast in our resolve to defeat this disease. We are passionately dedicated to lighting the way so every patient has a reason to hope.

The format of our Annual Report is among the changes taking place at HCI. Being mindful of the environment, this small printed document provides a glimpse of what you'll find in expanded stories online. Discover more about HCI's first decade:

www.huntsmancancer.org/annualreport2009



Jon M. and Karen Huntsman
Founders and Principal Benefactors








Mary Beckerle, PhD
Executive Director



Huntsman Cancer Institute is part of the University of Utah Health Care system.



Financial Data FY09



***NOTES:**

- Clinical revenues and expenditures of HCH are not included in these amounts. Refer to the University of Utah Health Care annual report.
- Additional funds for HCI programs are also budgeted through University of Utah administration and academic departments.

*Impact
Influence
History
Longevity
Future
Vision*



2009 ANNUAL REPORT

Cutting-Edge Cancer Research Programs

What is the spark that motivates ordinary men and women to become extraordinary cancer investigators? HCI's five research programs bring together more than 130 scientists and physicians who collaborate across disciplines and specialties to conduct world-renowned cancer research. In 2009 alone, approximately 100 scientific papers were published and \$54 million of funds were secured for 234 distinct projects. Find out what drives the leaders of these programs and how they work to make a difference in the lives of cancer patients.



David Bearss, PhD, and Sunil Sharma, MD

"To bring not just one, but many phase I trials to this state is unprecedented. It's a real benefit to the people of Utah, and I'm proud to be a part of it."

David Bearss, PhD
Co-Director, Center for Investigational Therapeutics

Investigational Therapeutics Offer the Last, Best Hope

For patients like Donald, a phase I clinical trial may be their last, best hope. "My particular type of cancer wasn't responding to conventional chemotherapy. The clinical trial was a possible avenue of treatment that nothing else seemed to provide." Phase I trials are studies of treatments tested in humans for the very first time. It is not easy to open a clinical trial, which is why they aren't common. But in 2009, HCI began the Center for Investigational Therapeutics, a phase I trial program that offers Utahns more options than ever before. Find out more.

A National Contender in the Cancer Fight

HCI is the only National Cancer Institute-Designated Cancer Center in the Intermountain West. That means our patients can take heart in knowing HCI is among the top cancer care and research institutions in the United States and across the world. Learn what it takes to be in the big leagues and why HCI is on the map when it comes to world-class cancer care.

From Lab Discovery to Life-Saving Screenings in Six Months

Genetics affects much more than the way we look on the outside. People with certain gene mutations are more susceptible to specific cancers. When an HCI researcher decided to study a gene called SDH5, he felt he was onto something. Only six months after a discovery about this cancer gene, patients at risk for paraganglioma, a head and neck cancer, were benefiting. Read the story.



New Presidential Professorships in Cancer Research

The economic downturn affects many aspects of life, but Jon M. and Karen Huntsman knew it mustn't impact cancer research. Find out how these philanthropists are helping five outstanding cancer researchers continue their innovative work.



MaryAnn Gerber, Cancer Survivor

"Vanity Almost Killed Me"

MaryAnn Gerber loved the way she looked with a tan. As a teenager, she visited a tanning salon almost every week. A few years later she noticed a pink mole on her face. Doctors discovered it was melanoma. "Vanity almost killed me," she says. Read her story and learn how HCI's free annual skin cancer screening clinic provides lifesaving care to Utahns.

Personalizing Treatment for Breast Cancer Patients

Breast cancer isn't just one disease—it comes in several subtypes. After studying more than a thousand genes, HCI researchers honed in on 50 that help categorize breast cancer tumors. Learn how doctors can now use the information to give patients treatments that will work best for their specific type of breast cancer.

"We hope the Breast Bioclassifier will give women peace of mind, knowing that we're diagnosing cancer more accurately than ever before."

Philip Bernard, MD
HCI Investigator



First Worldwide Genetic Testing Guidelines for Melanoma

Five to 10 percent of melanomas, the most deadly of all skin cancers, may be hereditary. As with most cancers, screening and early detection can make all the difference. Who, then, may benefit from genetic testing related to melanoma risk? In 2009, HCI led an international consortium of physicians and scientists to develop answers to this question. Learn how the first worldwide guidelines resulted.



Discovery Opens Potential of Cellular Reprogramming

Normally, when cells divide they give rise only to cells close to their own type. If scientists could encourage cells to undo this specificity (nudge skin cells to produce bone cells as well as skin cells, for example), that understanding might be used to generate tissues or organs that have been damaged through accident or disease such as cancer. Recently, two HCI investigators uncovered a mechanism to undo the program that sets cells on a specific pathway of behavior. It's one of many examples of HCI researchers working to eradicate cancer by understanding it from its very beginnings.



View the complete *Huntsman Cancer Institute 2009 Annual Report* online:
www.huntsmancancer.org/annualreport2009



A Decade of Influence

Highlights from the last 10 years

1999
HCI building dedicated; Cancer Learning Center opens, becoming one of the largest sources for cancer-related information in the Intermountain West

2000
Jon M. Huntsman pledges \$125 million to fund cancer research and construct hospital, bringing the family's total giving to \$225 million

2001
Special Populations Outreach to minority communities established; Familial Melanoma Research Clinic opens to conduct research into genetic causes and inheritance of skin cancer

2002
Sarcoma Array Research Consortium established to study molecular genetics of rare soft tissue and bone tumors; Familial Pancreatic Cancer Registry opens, aiming to discover genetic causes of pancreatic cancer

2003
National Cancer Institute awards HCI \$12.5 million grant to identify colon cancer genes and to examine cellular chemicals that may alter cell growth or cancer predisposition; studies of the *pinch* gene's role in cell adhesion provide clues about cancer metastasis

2004
Hospital opens, featuring first full-field digital mammography unit, first PET/CT imaging unit, and first facial prosthetics lab in the Intermountain West; HCI scientists develop a unique computational approach to predict the location of regulatory DNA across an entire genome

2005
Huntsman-Intermountain Cancer Care Program initiated, opening statewide research opportunities; Director's Translational Research Initiative established, promoting scientific advances and collaboration

2006
Cancer Clinical Research Database established, streamlining collection, maintenance, and access to cancer information; HCI conducts \$3.9 million Centers for Medicare & Medicaid Services project to improve cancer care among minority Medicare beneficiaries

2007
Cancer Center member Mario Capecchi wins Nobel Prize for gene targeting research; Utah Blood and Marrow Transplant and Myeloma Program opens, offering a unique approach to multiple myeloma treatment; first HCI-originated clinical trial goes statewide through the Huntsman-Intermountain Cancer Care Program

2008
Major hospital expansion begins; medical records from HCI and Intermountain Healthcare linked to the Utah Population Database, strengthening resources for genetics, health services, and public health studies; HCI researchers identify AFAP founder mutation, which may contribute to 1 percent of all colon cancers in the United States

2009
HCI celebrates 10 years; HCI researchers identify CTBP1 as the protein responsible for initiation of precancerous colon polyps, making more effective treatments possible

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

Impact Influence History Longevity Future Vision Impact Influence History Longevity Future Vision Impact Influence History Longevity